Ilumya · DIN 02516098 · 100 mg/mL · injection, 1 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 629 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 629 required
Write on scriptReason for Use code 629 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 629
Reason for Use code 629
For the treatment of severe plaque psoriasis (see Note 1 below) in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).
Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.
Approvals will only allow for standard dosing for Ilumya 100mg subcutaneously at weeks 0 and 4, and then every 12 weeks. Ilumya should not be used in combination with other systemic or biologic treatments for severe plaque psoriasis.
If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.
Note 1: Definition of severe plaque psoriasis:
- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face,
hands, feet or genital regions, AND
- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND
- Dermatology Life Quality Index (DLQI) score of at least 10.
Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:
- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND
- 12 week trial of phototherapy (unless not accessible), AND
- 6 month trial of at least 2 systemic, oral agents used alone or in combination
- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine
Maintenance/Renewal:
After 3 months of therapy, patients who respond to therapy should have:
- at least 75% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ilumya · DIN 02516098
Manufacturer: Sun Pharma; listing date 2022-02-28
Health Canada: Marketed since 2022-10-24 · brand ILUMYA · ATC L04AC17 TILDRAKIZUMAB · form Solution · route Subcutaneous · ingredients TILDRAKIZUMAB 100 MG/ML · company Sun pharmaceutical industries limited · schedule Prescription, Schedule d
Ilumya: Formulary list price $4935.00 per unit (the source does not state the unit; exact figure $4935.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02516098)
Source record
DIN 02516098: Ilumya
Raw flags: sec12=Y, sec3=Y
Item: 849200007; group id 874; item number 2113; lccId 00356; manufacturer id SPC
Source form: Inj Sol-1mL Pref Syr (Preservative-Free); strength: 100mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4935.0000; ministry $4935.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02516098
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100544
Shortage status: not checked (no credentials)